europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

EuropaBio Statement on the Evaluation of the Cross-Border Healthcare Directive

16/05/2022
STATEMENT
EuropaBio welcomes the publication of the evaluation of Directive 2011/24/EU on the application of patients’ rights to cross-border healthcare (Cross-Border Healthcare Directive) on 12 May 2022. The Directive is an essential tool to improve patient access to high-quality care, especially to specialised treatments such as advanced therapies and orphan medicines. EuropaBio believes that a well-functioning EU cross-border healthcare framework is necessary to enable patient access to specialised treatments and novel therapies when these are not available in their home country.

EuropaBio takes notes of the findings of the evaluation of the Directive and acknowledges that the Directive has facilitated access to cross-border care to some extent, and that the European Reference Networks bring a real EU-added value. Nonetheless, the evaluation reveals the limited success of the Directive to date, as exemplified by the small number of EU citizens aware of and making use of possibilities offered by the Directive, the disproportionate administrative burden, and continued uncertainty about costs abroad and reimbursement. After more than ten years, the Directive’s objectives have not been fully realised for the benefit of patients, and serious gaps remain.

EuropaBio regrets the lack of ambition for the Directive and urges the European Commission to revise the Directive to address the shortcomings highlighted by the evaluation. It is necessary to address persisting barriers, such as long approval times, fragmented payment and reimbursement processes, difficult access to clinical trials, and disjointed implementation that hinders patients’ access to excellence of care and innovative therapies. In addition, EuropaBio calls upon the Commission to convene a structured dialogue with the Member States and other stakeholders to ensure better functioning of the Directive’s implementing measures.

EuropaBio shares the Commission’s objective to improve access to innovative therapies and medicines across the EU and believes that a revision of the Directive to improve cross-border healthcare would help to achieve this objective. EuropaBio is committed to engage with the European Commission, policymakers, and other stakeholders to discuss ways to make the cross-border healthcare mechanisms work better for patient access to advanced therapies in the EU.

EuropaBio Statement on the evaluation of the Cross-Border Healthcare Directive


Download
2022_05_H_S_CBHDDownload
Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
16/03/2023

Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member